Takis s.r.l, Via di Castel Romano 100, 00128, Rome, Italy.
Evvivax s.r.l, Via di Castel Romano, 100, 00128, Rome, Italy.
J Transl Med. 2020 Jun 3;18(1):222. doi: 10.1186/s12967-020-02392-y.
COVID-19 has rapidly spread all over the world, progressing into a pandemic. This situation has urgently impelled many companies and public research institutes to concentrate their efforts on research for effective therapeutics. Here, we outline the strategies and targets currently adopted in developing a vaccine against SARS-CoV-2. Based on previous evidence and experience with SARS and MERS, the primary focus has been the Spike protein, considered as the ideal target for COVID-19 immunotherapies.
COVID-19 已迅速在全球蔓延，演变成大流行。这种情况紧急促使许多公司和公共研究机构集中精力研究有效的治疗方法。在这里，我们概述了目前开发针对 SARS-CoV-2 疫苗所采用的策略和靶标。基于以前对 SARS 和 MERS 的证据和经验，主要关注点是 Spike 蛋白，它被认为是 COVID-19 免疫疗法的理想靶标。
